On Monday, Cidara Therapeutics Inc (NASDAQ: CDTX) opened lower -5.43% from the last session, before settling in for the closing price of $101.99. Price fluctuations for CDTX have ranged from $10.14 to $106.63 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 1.30% over the last five years. Company’s average yearly earnings per share was noted 77.20% at the time writing. With a float of $19.37 million, this company’s outstanding shares have now reached $23.23 million.
Cidara Therapeutics Inc (CDTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cidara Therapeutics Inc is 23.61%, while institutional ownership is 84.52%. The most recent insider transaction that took place on Sep 11 ’25, was worth 29,797. In this transaction Chief Medical Officer of this company sold 474 shares at a rate of $62.86, taking the stock ownership to the 31,418 shares. Before that another transaction happened on Jun 26 ’25, when Company’s Director bought 2,272,727 for $44.00, making the entire transaction worth $99,999,988. This insider now owns 3,365,523 shares in total.
Cidara Therapeutics Inc (CDTX) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -2.38 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -5.44) by 3.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.92% during the next five years compared to 1.30% growth over the previous five years of trading.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
Check out the current performance indicators for Cidara Therapeutics Inc (CDTX). In the past quarter, the stock posted a quick ratio of 16.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -11.14, a number that is poised to hit -1.39 in the next quarter and is forecasted to reach -7.76 in one year’s time.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Analysing the last 5-days average volume posted by the [Cidara Therapeutics Inc, CDTX], we can find that recorded value of 1.16 million was better than the volume posted last year of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 80.67%.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 88.40%, which indicates a significant increase from 76.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 6.66 in the past 14 days, which was higher than the 3.79 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $69.94, while its 200-day Moving Average is $37.67. Now, the first resistance to watch is $102.56. This is followed by the second major resistance level at $108.68. The third major resistance level sits at $111.78. If the price goes on to break the first support level at $93.34, it is likely to go to the next support level at $90.24. Should the price break the second support level, the third support level stands at $84.12.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
There are currently 25,358K shares outstanding in the company with a market cap of 2.45 billion. Presently, the company’s annual sales total 1,280 K according to its annual income of -169,830 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -25,720 K.
